East cancer, pancreatic cancer Monotherapy in patients with deleterious or suspected deleterious germline Brca mutated (as detected by an FDa-approved test) sophisticated ovarian cancer who've been treated with three or extra prior lines of chemotherapy ALL, GIST, dermatofibrosarcoma protuberans, CML, myelodysplastic syndrome, systemic mastocytosis advance renal cell carcinoma, some hepatocellular